ESOC 2025 | Thrombus-based inflammatory gene expression profiles to identify etiology of stroke
Gerrit M. Grosse, MD, PhD, University Hospital Basel, Basel, Switzerland, discusses the potential of analyzing retrieved thrombi from stroke patients to identify distinct patterns of cytokine levels that can help differentiate between cerebral large vessel occlusion strokes. Dr Grosse highlights the finding that the cryptogenic group lies between the cardioembolic and large artery groups, suggesting that cytokine profiles could be used to guide the assignment of secondary preventive measures. This work aims to be validated in external cohorts before its findings can be applied in clinical practice. This interview took place at the 11th European Stroke Organisation Conference (ESOC) in Helsinki, Finland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
We did work where we investigated thrombi that have been retrieved during thrombectomy from stroke patients. We did a panel analysis using NanoString technology and could nicely show in this pilot work that there are really distinct patterns of cytokine levels within these clots that are different between large artery atherosclerotic origin, cardioembolic origin and cryptogenic origin...
We did work where we investigated thrombi that have been retrieved during thrombectomy from stroke patients. We did a panel analysis using NanoString technology and could nicely show in this pilot work that there are really distinct patterns of cytokine levels within these clots that are different between large artery atherosclerotic origin, cardioembolic origin and cryptogenic origin. And the most intriguing thing in this work is that the cryptogenic group lies exactly between the cardioembolic and the large artery group, meaning that the overlaps between the concentrations of these distinct groups could really help us to guide whether the clot is actually from a vascular origin or from a cardioembolic origin. And that could then in the future potentially help us to assign the appropriate secondary preventive measure. But, of course, these findings need to be also validated in external cohorts before.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
